We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
PacBio beat first-quarter estimates with higher margins and a narrower adjusted operating loss.
PACB's Revio and Vega systems drove adoption across research, clinical, and academic markets.
PacBio targets $45 to $50 million in annual cost savings via restructuring by the end of 2025.
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent first-quarter results, is expected to contribute further. However, the concern about long purchasing cycles persists.
In the year-to-date period, this Zacks Rank #2 (Buy) company’s shares have lost 43.8% compared with a 9.2% decline of the industry. The S&P 500 Composite has improved 0.8% in the said time frame.
The renowned global provider of sequencing systems has a market capitalization of $315.1 million. The company projects 19.3% growth for 2025 and expects to maintain its strong performance going forward. PacBio’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and met once, delivering an average surprise of 13.2%.
Image Source: Zacks Investment Research
Factors Favoring PACB’s Growth
Sequencing Technologies Strengthen Market Leadership:PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology, which enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes, and epigenetic modifications.
The global SMRT market, valued at $2.74 billion in 2023, is projected to reach $4.14 billion by 2031, witnessing a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating Sequencing by Binding chemistry with the launch of its Onso system in 2022, a short-read platform delivering ≥90% of bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By providing both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while driving down costs and enhancing variant detection.
Robust Product Portfolio Driving Growth: PacBio’s diverse and expanding product portfolio is driving strong adoption across research, clinical, and population genomics markets. The company’s flagship Revio system continues to be the primary growth driver, with 97 units shipped in 2024, bringing the total installed base to nearly 200 customers. Revio’s high-throughput capabilities, enhanced by the recent Spark chemistry upgrade, have significantly improved performance, delivering up to 46% more yield per SMRT Cell and requiring substantially lower DNA input.
Additionally, the introduction of the Vega benchtop platform has opened new avenues for growth by offering a compact, lower-cost system ideal for academic, core facility, and smaller clinical labs. In the first quarter of 2025, 28 Vega systems were shipped, with approximately 50% to new PacBio customers, showcasing the platform’s ability to expand the company’s reach.
Solid Q1 Results: PacBio exited the first quarter of 2025 with better-than-expected results, where both earnings and revenues beat their respective Zacks Consensus Estimate. A robust increase in its Service and other revenues was encouraging. The expansion of the adjusted gross margin and reduction in adjusted operating loss also bode well.
During the quarter, PacBio initiated a company-wide restructuring plan aimed at reducing operating expenses and sharpening its strategic focus on the long-read sequencing business. This initiative is projected to lower annualized adjusted operating expenses by approximately $45 million to $50 million by the end of 2025, streamlining the company's resources toward its core strengths.
A Factor That May Offset the Gains for PACB
Longer Purchasing Cycles: PacBio is facing longer sales cycles for its high-cost Revio sequencing system as customers navigate funding uncertainties and tighter capital budgets. The company has reported that academic and government-backed institutions, particularly in the United States, are delaying purchasing decisions due to budget freezes and funding constraints at the National Institutes of Health. Additionally, macroeconomic pressures in the Asia-Pacific region are contributing to slower procurement timelines, further affecting instrument sales. These delays in customer decision-making could limit near-term revenue growth and create quarterly revenue volatility.
Estimate Trend
PacBio has been witnessing a positive estimate revision trend for 2025. Over the past 30 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed 5 cents to 67 cents.
The Zacks Consensus Estimate for revenues for 2025 is pegged at $155.1 million, indicating a 0.7% increase from the year-ago reported numbers.
Other Key Picks
Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Add PacBio Stock to Your Portfolio Now
Key Takeaways
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent first-quarter results, is expected to contribute further. However, the concern about long purchasing cycles persists.
In the year-to-date period, this Zacks Rank #2 (Buy) company’s shares have lost 43.8% compared with a 9.2% decline of the industry. The S&P 500 Composite has improved 0.8% in the said time frame.
The renowned global provider of sequencing systems has a market capitalization of $315.1 million. The company projects 19.3% growth for 2025 and expects to maintain its strong performance going forward. PacBio’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and met once, delivering an average surprise of 13.2%.
Image Source: Zacks Investment Research
Factors Favoring PACB’s Growth
Sequencing Technologies Strengthen Market Leadership:PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology, which enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes, and epigenetic modifications.
The global SMRT market, valued at $2.74 billion in 2023, is projected to reach $4.14 billion by 2031, witnessing a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating Sequencing by Binding chemistry with the launch of its Onso system in 2022, a short-read platform delivering ≥90% of bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By providing both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while driving down costs and enhancing variant detection.
Robust Product Portfolio Driving Growth: PacBio’s diverse and expanding product portfolio is driving strong adoption across research, clinical, and population genomics markets. The company’s flagship Revio system continues to be the primary growth driver, with 97 units shipped in 2024, bringing the total installed base to nearly 200 customers. Revio’s high-throughput capabilities, enhanced by the recent Spark chemistry upgrade, have significantly improved performance, delivering up to 46% more yield per SMRT Cell and requiring substantially lower DNA input.
Additionally, the introduction of the Vega benchtop platform has opened new avenues for growth by offering a compact, lower-cost system ideal for academic, core facility, and smaller clinical labs. In the first quarter of 2025, 28 Vega systems were shipped, with approximately 50% to new PacBio customers, showcasing the platform’s ability to expand the company’s reach.
Solid Q1 Results: PacBio exited the first quarter of 2025 with better-than-expected results, where both earnings and revenues beat their respective Zacks Consensus Estimate. A robust increase in its Service and other revenues was encouraging. The expansion of the adjusted gross margin and reduction in adjusted operating loss also bode well.
During the quarter, PacBio initiated a company-wide restructuring plan aimed at reducing operating expenses and sharpening its strategic focus on the long-read sequencing business. This initiative is projected to lower annualized adjusted operating expenses by approximately $45 million to $50 million by the end of 2025, streamlining the company's resources toward its core strengths.
A Factor That May Offset the Gains for PACB
Longer Purchasing Cycles: PacBio is facing longer sales cycles for its high-cost Revio sequencing system as customers navigate funding uncertainties and tighter capital budgets. The company has reported that academic and government-backed institutions, particularly in the United States, are delaying purchasing decisions due to budget freezes and funding constraints at the National Institutes of Health. Additionally, macroeconomic pressures in the Asia-Pacific region are contributing to slower procurement timelines, further affecting instrument sales. These delays in customer decision-making could limit near-term revenue growth and create quarterly revenue volatility.
Estimate Trend
PacBio has been witnessing a positive estimate revision trend for 2025. Over the past 30 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed 5 cents to 67 cents.
The Zacks Consensus Estimate for revenues for 2025 is pegged at $155.1 million, indicating a 0.7% increase from the year-ago reported numbers.
Other Key Picks
Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.